Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Prodromal Alzheimers Disease: Successive Emergence of the Clinical Symptoms
Ann Neurol 64:492-498,479, Amieva,H.,et al, 2008
A 32-Year Prospective Study of Change in Body Weight and Incident Dementia
Arch Neurol 62:55-60,20, Stewart,R.,et al, 2005
A 10-Item Smell Identification Scale Related to Risk for Alzheimers Disease
Ann Neurol 58:155-160, Taberr,M.H.,et al, 2005
Idiopathic Hyposmia As a Preclinical Sign of Parkinson's Disease
Ann Neurol 56:173-181,169, Ponsen,M.M.,et al, 2004
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Functional Deficits in Patients with Mild Cognitive Impairment
Neurol 58:758-764, Tabert,M.H.,et al, 2002
Incidence and Outcome of Mild Cognitive Impairment in a Population-Based Prospective Cohort
Neurol 59;1594-1599, Larrieu,S.,et al, 2002
Early Detection of Dementia: Mild Cognitive Impairment (an Evidence-based Review)
Neurol 56:1133-1142, 1131, Petersen,R.C.,et al, 2001
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Might Olfactory Dysfunction be a Marker of Early Alzheimer's Disease?
Lancet 355:84-85, Burns,A., 2000
Striatal Dopamine Trnasporter Binding Assessed by [I-123]IPT and Single Photon Emission Computed tomography in Patients with Early Parkinson's Disease, Implications for a Preclinical Diagnosis
Arch Neurol 57:205-208, Schwarz,J.,et al, 2000
The Preclinical Phase of Alzheimer Disease
Arch Neurol 57:808-813, Elias,M.F.,et al, 2000
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
NEJM 343:450-456,502, Bookheimer,S.Y. et al, 2000
The Value of Informant Versus Individual's Complaints of Memory Impairment in Early Dementia
Neurol 55:1724-1726, Carr,D.B.,et al, 2000
Serial Magnetic Resonance Imaging of Cerebral Atrophy in Preclinical Alzheimer's Disease
Lancet 353:2125, Fox,N.C.,et al, 1999
Preclinical Prediction of Alzheimer's Disease Using SPECT
Neurol 50:1563-1571, Johnson,K.A.,et al, 1998
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
Neuropsychological Detection and Characterization of Preclinical Alzheimer's Disease
Neurol 45:957-962, Jacobs,D.M.,et al, 1995
Clinical and[18F]dopa PET Findings in Early Parkinson's Disease
JNNP 59:597-600, Morrish,P.K.,et al, 1995
PET Imaging of the Dopamine Transporter with 11C-WIN 35, 428 Reveals Marked Declines in Mild Parkinson's Disease
Ann Neurol 34:423-431, Frost,J.J.,et al, 1993
Preclinical Detection of Parkinson's Disease
Neurology Suppl 2, 41:5-921991., Koller,W.C.&Langston,J.W., 1991